Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 144Other hematologic neoplasm 74Plasma cell 4CNS 4Myeloid 3Gastrointestinal 3Thoracic 2Genitourinary 2Classical hematology 2Tumor-Agnostic 1NET 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × ibrutinib × Genitourinary × Clear all
NCT02899078 2025-05-18

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

University of California, Davis

Phase 1/2 Completed
31 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell

NCT02643667 2025-01-08

Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Washington University School of Medicine

Phase 2 Completed
27 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡